Movement Alert｜Guardant Health Inc. Rises 10.72% in Regular Trading, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised

Market Focus07-31

On July 31, Guardant Health Inc. rose 10.72% in regular trading, trading at $168.31/share, with turnover of $164 million. The surge was driven by the company's Q2 earnings release, which showed revenue significantly exceeding market expectations along with an upward revision to full-year guidance.

Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year and well above the analyst consensus estimate of $314.2 million. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier. The company raised its full-year 2026 revenue guidance to $1.34 billion–$1.36 billion, up from the prior range of $1.30 billion–$1.32 billion, surpassing the FactSet estimate of $1.31 billion.

The strong results were further supported by multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple cancer therapies, inclusion of its Shield blood test in American Cancer Society colorectal cancer screening guidelines, and target price increases from BofA Securities, RBC Capital Markets, and Evercore ISI.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122616363?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122616363","market":"us","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Inc. Rises 10.72% in Regular Trading, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On July 31, Guardant Health Inc. rose 10.72% in regular trading, trading at $168.31/share, with turnover of $164 million. The surge was driven by the company's Q2 earnings release, which showed revenue significantly exceeding market expectations along with an upward revision to full-year guidance.</p><p>Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year and well above the analyst consensus estimate of $314.2 million. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier. The company raised its full-year 2026 revenue guidance to $1.34 billion–$1.36 billion, up from the prior range of $1.30 billion–$1.32 billion, surpassing the FactSet estimate of $1.31 billion.</p><p>The strong results were further supported by multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple cancer therapies, inclusion of its Shield blood test in American Cancer Society colorectal cancer screening guidelines, and target price increases from BofA Securities, RBC Capital Markets, and Evercore ISI.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Inc. Rises 10.72% in Regular Trading, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Inc. Rises 10.72% in Regular Trading, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, Guardant Health Inc. rose 10.72% in regular trading, trading at $168.31/share, with turnover of $164 million. The surge was driven by the company's Q2 earnings release, which showed revenue significantly exceeding market expectations along with an upward revision to full-year guidance.</p><p>Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year and well above the analyst consensus estimate of $314.2 million. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier. The company raised its full-year 2026 revenue guidance to $1.34 billion–$1.36 billion, up from the prior range of $1.30 billion–$1.32 billion, surpassing the FactSet estimate of $1.31 billion.</p><p>The strong results were further supported by multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple cancer therapies, inclusion of its Shield blood test in American Cancer Society colorectal cancer screening guidelines, and target price increases from BofA Securities, RBC Capital Markets, and Evercore ISI.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1122616363","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122616363","pubTimestamp":1785506208,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Guardant Health Inc. rose 10.72% in regular trading, trading at $168.31/share, with turnover of $164 million. The surge was driven by the company's Q2 earnings release, which showed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"走势警报|Guardant Health Inc. 常规交易上涨 10.72%，第二季度收入大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On July 31, Guardant Health Inc. rose 10.72% in regular trading, trading at $168.31/share, with turnover of $164 million. The surge was driven by the company's Q2 earnings release, which showed revenue significantly exceeding market expectations along with an upward revision to full-year guidance.Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year and well above the analyst consensus estimate of $314.2 million. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier. The company raised its full-year 2026 revenue guidance to $1.34 billion–$1.36 billion, up from the prior range of $1.30 billion–$1.32 billion, surpassing the FactSet estimate of $1.31 billion.The strong results were further supported by multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple cancer therapies, inclusion of its Shield blood test in American Cancer Society colorectal cancer screening guidelines, and target price increases from BofA Securities, RBC Capital Markets, and Evercore ISI.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122616363","isCrawlerRequest":true}